Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. [electronic resource]
Producer: 20140418Description: 573-81 p. digitalISSN:- 1526-632X
- Adult
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antigens, CD19 -- biosynthesis
- Antigens, CD20 -- administration & dosage
- Double-Blind Method
- Evidence-Based Medicine -- methods
- Female
- Humans
- Male
- Middle Aged
- Multiple Sclerosis, Relapsing-Remitting -- blood
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.